

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

Paper No.

06/23/2008

Edwards Lifesciences LLC Legal Dept. One Edwards Way Irvine, CA 92614

Application No.:	10/789,181	Date Mailed:	06/23/2008
First Named Inventor:	Mooney, Charles, R.	Examiner:	VU, QUYNH-NHU HOANG
Attorney Docket No.:	ECC-5062CIP2DIV	Art Unit:	3763
Confirmation No.:	6985	Filing Date:	02/26/2004

Please find attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) Notice of Non-Compliant Amendment 10/789,181 MOONEY ET AL. (37 CFR 1.121) Art Unit 1700

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

requiren		CFR 1.121 or 1.4.			because it has failed to meet the be compliant, correction of the following
	1. Amend A. A B. N	ments to the specifi Amended paragraph		arkings.	MENT TO BE NON-COMPLIANT:
			separate sheet. 37 C	FR 1.72.	
	☐ A.]	'Annotated Sheet" a The practice of subn	ot properly identified in serequired by 37 CFI mitting proposed draw	R 1.121(d). ring correction has b	"Replacement Sheet," "New Sheet," or been eliminated. Replacement drawings with 37 CFR 1.84 are required.
	A. A. B. 1	The listing of claims Each claim has not leach claim canno number by using on Previously presente	all of the claims is not does not include the been provided with the to be identified. Note: e of the following stated), (New), (Not entendment paper have	text of all pending on the proper status ider the status of every tus identifiers: (Origi red), (Withdrawn) ar	laims (including withdrawn claims) ntifler, and as such, the individual status claim must be indicated after its claim nal), (Currently amended), (Canceled), d (Withdrawn-currently amended), d in ascending numerical order.
			nt is unsigned or not a d by 37 CFR 1.121, s		e with 37 CFR 1.4): For further explanation
 App filed 	olicant is giv I after allov	ven no new time per vance, or a drawing		liant amendment is applicant wishes to	an after-final amendment or an amendment resubmit the non-compliant after-final submitted.
corr (incl ame Qua	ection, if the luding a su endment file ayle action.	e non-compliant an bmission for a requ ed within a suspens If any of above box	nendment is one of the est for continued exa ion period under 37 (e following: a prelimination (RCE) und CFR 1.103(a) or (c), d, the correction req	the mail date of this notice to supply the inary amendment, a non-final amendment er 37 CFR 1.114), a supplemental and an amendment filed in response to a uired is only the corrected section of the
a	mendment Failure to t Abando filed in re	t or an amendment imely respond to the nment of the applice esponse to a Quayle ry of the amendment	filed in response to a nis notice will result in ation if the non-comp a action; or	Quayle action. n: liant amendment is	n-compliant amendment is a non-final a non-final amendment or an amendment reliminary amendment or supplemental
Legal In	struments	Examiner (LIE), if a	pplicable /MAMYE W	AGSTAFF/	Telephone No: (571)272-1057

U.S. Patent and Trademark Office

Continuation of 4. Other: Each amended section should begin on a separte sheet. The remarks start on the same page as the amended claims.